TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06975293: STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

Sponsor: STORM Therapeutics LTD · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 107 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$2,159,850

Rescue Site Savings

+$1,413,720

Unlock Full NCT06975293 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06975293 Rescue Dossier →